Prof-Fabrice Carrat

Hepatitis C: Study finds Direct Acting Antivirals Reduce Mortality and Liver Cancer Interview with:

Prof-Fabrice Carrat

Prof. Carrat,

Prof. Fabrice Carrat, MD, PhD
Institut Pierre Louis d’Épidémiologie et de Santé Publique,
Paris, France What is the background for this study?  

Response: Most studies on direct acting antivirals were focused on sustained vriological response (SVR) rates, but few studies addressed the issue of clinical outcomes. What are the main findings?

Response: Treatment of hepatitis C with direct acting antivirals (DAA) is associated with reduced risk of mortality and liver cancer. What should readers take away from your report?

Response: This suggests that direct acting antivirals should be considered for all patients with chronic hepatitis C infection. What recommendations do you have for future research as a result of this work?

Response: Follow-up of cohort participants will continue to assess the long term impact of DAA on clinical outcomes, namely: decompensated cirrhosis (in patients with cirrhosis); residual risk of hepatocellular carcinoma, regression of  liver fibrosis and morbidity not related to the liver (particulary cardiovascular events). 

Disclosures: The study was sponsored by ANRS_INSERM  


Fabrice Carrat, Hélène Fontaine, Céline Dorival, Mélanie Simony, Alpha Diallo, Christophe Hezode, Victor De Ledinghen, Dominique Larrey, Georges Haour, Jean-Pierre Bronowicki, Fabien Zoulim, Tarik Asselah, Patrick Marcellin, Dominique Thabut, Vincent Leroy, Albert Tran, François Habersetzer, Didier Samuel, Dominique Guyader, Olivier Chazouilleres, Philippe Mathurin, Sophie Metivier, Laurent Alric, Ghassan Riachi, Jérôme Gournay, Armand Abergel, Paul Cales, Nathalie Ganne, Véronique Loustaud-Ratti, Louis D’Alteroche, Xavier Causse, Claire Geist, Anne Minello, Isabelle Rosa, Moana Gelu-Simeon, Isabelle Portal, François Raffi, Marc Bourliere, Stanislas Pol. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. The Lancet, 2019; DOI: 10.1016/S0140-6736(18)32111-1




[wysija_form id=”3″]






The information on is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.


Last Updated on February 14, 2019 by Marie Benz MD FAAD